SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer

Molecular Cancer Therapeutics

Volumn 2, Issue 5, 2003, Pages 471-478

  Abrams, Tinya J ^a   Lee, Leslie B ^a   Murray, Lesley J ^a   Pryer, Nancy K ^a   Cherrington, Julie M ^a  

^a SUGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650874372     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chia, M. M., Gazdar, A. F., Carone, D. P., and Minna J. P. Biology of lung cancer. In: J. F. Murray and J. A. Nadel (eds.). Textbook of Respiratory Medicine, 2nd ed., pp. 1485-1503. Philadelphia: W. B. Saunders, 1994.
2. Murren, J., Glatstein, E., and Pass, H. I. Small cell lung cancer. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles & Practice of Oncology, 6th ed., pp. 983-1018. Philadelphia: Lippincott Williams & Wilkins, 1993.
3. Lev, S., Blechman, J. M., Givol, D., and Yarden, Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit. Rev. Oncog., 5: 141-168, 1994.
4. Krystal, G. W., Hines, S. J., and Organ, C. P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.
5. Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C. J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D., and Fletcher, J. A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol., 156: 791-795, 2000. (Pubitemid 30626936)
6. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., and Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash. DC), 279: 577-580, 1998. (Pubitemid 28067289)
7. Boissan, M., Feger, F., Guillosson, J. J., and Arock, M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J. Leukocyte Biol., 67: 135-148, 2000.
8. Krystal, G. W., Carlson, P., and Litz, J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res., 57: 2203-2208, 1997. (Pubitemid 27247039)
9. Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., and Lipson, K. E. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res., 61: 3660-3668, 2001. (Pubitemid 32694977)
10. Krystal, G. W., Honsawek, S., Litz, J., and Buchdunger, E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res., 6: 3319-3326, 2000. (Pubitemid 30637763)
11. Wang, W. L., Healy, M. E., Sattler, M., Verma, S., Lin, J., Maulik, G., Stiles, C. D., Griffin, J. D., Johnson, B. E., and Salgia, R. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene, 19: 3521-3528, 2000. (Pubitemid 30487449)
12. Mendel, D. B., Laird, A. D., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R. E., Abrams, T. J., Ngai, T. J., Lee, L. B., Murray, L. J., Carver, J., Chan, E., Moss, K. G., Haznedar, J. O., Sukbuntherng, J., Blake, R. A., Sun, C., Tang, C., Miller, T., Shirazian, S., McMahon, G. and Cherrington, J. M. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res., 9: 327-337, 2002. (Pubitemid 36109749)
13. O'Farrell, A. M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W. M., Lee, L. B., Town, A., Smolich, B. D., Manning, W. C., Murray, L. J., Heinrich, M. C., and Cherrington, J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood, in press, 2003.
14. Cherrington, J. M., Strawn, L. M., and Shawver, L. K. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. In: G. Klein and G. F. Vande Woude (eds.), Advances in Cancer Research, 1st ed., pp. 1-38. San Diego, CA: Academic Press, 2000.
15. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
16. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., and Druker, B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997. (Pubitemid 28007210)
17. Wolff, N. C., and Ilaria, R. L., Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood, 98: 2808-2816, 2001.
18. Sjoblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Dal Cin, P., Buchdunger, E., Dumanski, J. P., Ostman, A., and Heldin, C-H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res., 61: 5778-5783, 2001.
19. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. (Bethesda), 91: 163-168, 1999.
20. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., and Lydon, N. B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther., 295: 139-145, 2000.
21. Schiller, J. H. Current standards of care in small-cell and non-small-cell lung cancer. Oncology (Basel), 61 (Suppl.): 3-13, 2001.
22. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., and Takagi, H. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991. (Pubitemid 21924076)
23. Plummer, H., III, Catlett, J., Leftwich, J., Armstrong, B., Carlson, P., Huff, T., and Krystal, G. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res., 53: 4337-4342, 1993. (Pubitemid 24146787)
24. Rygaard, K., Nakamura, T., and Spang-Thomsen, M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer, 67: 37-46, 1993. (Pubitemid 23034921)
25. Siziopikou, K. P., Cosar, E., Morgan, M., and Husain, A. N. Differential expression of c-kit in lung carcinomas; implications for possible use of the tyrosine kinase inhibitor STI571 in lung cancer. Proc. Am. Assoc. Cancer Res., 43: 755-756, 2002.
26. Leflunomide approved for rheumatoid arthritis; other drugs nearing approval. Am. J. Health Syst. Pharm., 55: 2225-2226, 1998.
27. Pederson, L., Winding, B., Foged, N. T., Spelsberg, T. C., and Oursler, M. J. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res., 59: 5849-5855, 1999.
28. Dvorak, H. F., Detmar, M., Claffey, K. P., Nagy, J. A., van de Water, L., and Senger, D. R. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int. Arch. Allergy Immunol., 107: 233-235, 1995.
29. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996. (Pubitemid 26272076)
30. Salven, P., Ruotsalainen, T., Mattson, K., and Joensuu, H. High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer, 79: 144-146, 1998. (Pubitemid 28201685)
31. Mall, J. W., Schwenk, W., Philipp, A. W., Meyer-Kipker, C., Mall, W., Muller, J., and Pollmann, C. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology, 7: 99-102, 2002. (Pubitemid 34662939)
32. Lucchi, M., Mussi, A., Fontanini, G., Faviana, P., Ribechini, A., and Angeletti, C. A. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. Cardio-thoracic Surg., 21: 1105-1110, 2002.